US Lawmakers Call for Curbs on Clinical Trial Collaborations Linked to Chinese Military

The proposed restrictions will ‘help ensure U.S. biotechnology does not fall into the hands’ of the Chinese regime, said lawmakers.

Rep. Raja Krishnamoorthi (D-Ill.) (L), ranking member of the House Select Committee on the Chinese Communist Party, and Rep. John Moolenaar (R-Mich.), the committee chairman, speak at the American Enterprise Institute in Washington on Sept. 25, 2024. Madalina Vasiliu/The Epoch Times

A bipartisan group of lawmakers has asked the U.S. government to consider new rules restricting U.S. biotech companies from conducting clinical trials with entities linked to the Chinese military.

In a Jan. 9 letter to Commerce Secretary Gina Raimondo, the House Select Committee on the Chinese Communist Party said the proposed restrictions will “help ensure U.S. biotechnology does not fall into the hands of the PRC,” referring to the acronym of communist China’s official name, the People’s Republic of China.